Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
2045 studies found for:    melanoma
Show Display Options
Rank Status Study
1 Recruiting Characterization of the Melanoma-Specific Immune Response
Condition: Melanoma
Intervention:
2 Completed
Has Results
Melanoma Perception and Health Literacy in People of Color
Condition: Melanoma
Interventions: Behavioral: ABCDEs of Melanoma Skin Cancer;   Behavioral: ABCDEs of Melanoma
3 Active, not recruiting Melanoma Risk-Reduction Among Patients and Family Members
Condition: Melanoma
Interventions: Behavioral: Questionnaire;   Behavioral: Interview
4 Not yet recruiting Tracing Dissemination of Melanoma Cells in Healthy Tissues
Condition: Melanoma
Intervention: Procedure: Melanoma and peritumoral skin excision
5 Recruiting Prospective Melanoma Database
Condition: Melanoma
Intervention: Other: clinical biological data collection on melanoma
6 Active, not recruiting Evaluation of the Immunogenicity of Vaccination With Multiple Synthetic Melanoma Peptides With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With Advanced Melanoma
Condition: Melanoma
Intervention: Biological: 4-peptide and 12-peptide melanoma vaccines
7 Not yet recruiting Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: Standard therapy or clinical trial;   Drug: Matched targeted therapy;   Drug: Trametinib and / or supportive care
8 Completed
Has Results
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma
Conditions: Melanoma;   Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody;   Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine
9 Completed Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma
Condition: Melanoma
Interventions: Biological: melanoma GVAX;   Drug: Cyclophosphamide
10 Recruiting Molecular Characterization of Advanced Stage Melanoma by Blood Sampling
Condition: Metastatic Melanoma
Intervention: Other: patients with metastatic melanoma
11 Recruiting Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma
Condition: Melanoma
Interventions: Drug: Dabrafenib;   Drug: Trametinib
12 Completed Trial for the Evaluation of the Effect of Systemic Low-dose Interleukin-2 (IL-2) on the Immunogenicity of a Vaccine Comprising Synthetic Melanoma Peptides Administered With Granulocyte-macrophage Colony-stimulating Factor (GM-CSF)-In-Adjuvant, in Patients With High Risk Melanoma
Condition: Melanoma
Interventions: Drug: low-dose IL-2;   Biological: melanoma vaccine
13 Unknown  Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma
Conditions: Advanced Melanoma;   Untreated Patients
Interventions: Drug: dacarbazine plus Endostar (Experimental group);   Drug: dacarbazine plus placebo (control group)
14 Active, not recruiting Vaccination Plus Ontak in Patients With Metastatic Melanoma
Condition: Melanoma
Interventions: Drug: 4-peptide melanoma vaccine;   Drug: 4-peptide melanoma vaccine plus Ontak;   Drug: ontak
15 Completed Comparison of Video-Based Versus Written Patient Education on Melanoma
Conditions: Melanoma;   Malignant Melanoma
Intervention: Other: Patient Educational Materials
16 Completed Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients
Condition: Melanoma
Intervention: Other: biological collection
17 Recruiting MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma
Condition: Cutaneous Melanoma by AJCC V7 Stage
Interventions: Procedure: Wide Local Excision = 1cm Margin;   Procedure: Wide Local Excision = 2cm Margin
18 Completed Pilot Study of Infrared Imaging of Cutaneous Melanoma
Condition: Melanoma
Intervention:
19 Terminated Temodar and Sutent as Therapy for Melanoma
Condition: Metastatic Malignant Melanoma
Intervention: Drug: Temozolomide and SU11248
20 Completed Clinical and Histological Features of Head and Neck Melanoma
Condition: Melanoma
Intervention: Other: Data collection

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.